In addition, as a regulatory target of GCKR, GCK has been developed as an effective and clinically applicable oral hypoglycemic agent (e.g., Dorzagliatin), which implies the feasibility of targeting GCKR for the development of drugs for GDM [33, 34]. Here, GCKR is linked to gestational diabetes.